Education
About Us
Working with TipRanks
Follow Us
Can-Fite BioPharma (CANF)
XASE:CANF
Total Valuation
Can-Fite BioPharma has a market cap or net worth of $10.42M. The enterprise value is $12.49B.
Market Cap$10.42M
Enterprise Value$12.49B
Share Statistics
Can-Fite BioPharma has 2,142,545 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,142,545
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Can-Fite BioPharma’s return on equity (ROE) is -1.45 and return on invested capital (ROIC) is -114.17%.
Return on Equity (ROE)-1.45
Return on Assets (ROA)-0.86
Return on Invested Capital (ROIC)-114.17%
Return on Capital Employed (ROCE)-1.15
Revenue Per Employee134.80K
Profits Per Employee-1.58M
Employee Count5
Asset Turnover0.07
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Can-Fite BioPharma is ―. Can-Fite BioPharma’s PEG ratio is 0.75.
PE Ratio―
PS Ratio350.86
PB Ratio43.50
Price to Fair Value43.50
Price to FCF-30.94
Price to Operating Cash Flow-997.12
PEG Ratio0.75
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 674.00K and earned -7.88M in profits. Earnings per share was -1.08.
Revenue674.00K
Gross Profit674.00K
Operating Income-8.13M
Pretax Income-7.88M
Net Income-7.88M
EBITDA-8.12M
Earnings Per Share (EPS)-1.08
Cash Flow
In the last 12 months, operating cash flow was -8.35M and capital expenditures -2.00K, giving a free cash flow of -8.36M billion.
Operating Cash Flow-8.35M
Free Cash Flow-8.36M
Free Cash Flow per Share-3.90
Dividends & Yields
Can-Fite BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.00
52-Week Price Change-85.13%
50-Day Moving Average4.34
200-Day Moving Average11.35
Relative Strength Index (RSI)48.76
Average Volume (3m)258.05K
Important Dates
Can-Fite BioPharma upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateNov 21, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
Can-Fite BioPharma as a current ratio of 4.38, with Debt / Equity ratio of 2.15%
Current Ratio4.38
Quick Ratio4.38
Debt to Market Cap0.00
Net Debt to EBITDA0.58
Interest Coverage Ratio-580.71
Taxes
In the past 12 months, Can-Fite BioPharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Can-Fite BioPharma EV to EBITDA ratio is -28.53, with an EV/FCF ratio of -30.33.
EV to Sales343.86
EV to EBITDA-28.53
EV to Free Cash Flow-30.33
EV to Operating Cash Flow-30.35
Balance Sheet
Can-Fite BioPharma has $6.46M in cash and marketable securities with $90.00K in debt, giving a net cash position of $6.37M billion.
Cash & Marketable Securities$6.46M
Total Debt$90.00K
Net Cash$6.37M
Net Cash Per Share$2.97
Tangible Book Value Per Share$0.75
Margins
Gross margin is 100.00%, with operating margin of -1206.23%, and net profit margin of -1169.14%.
Gross Margin100.00%
Operating Margin-1206.23%
Pretax Margin-1169.14%
Net Profit Margin-1169.14%
EBITDA Margin-1205.19%
EBIT Margin-1206.23%
Analyst Forecast
The average price target for Can-Fite BioPharma is ―, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target―
Price Target Upside―
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―